Johnson & Johnson Statement on COVID-19 Vaccine (7/12)
NEW BRUNSWICK, N.J., July 12, 2021 – The safety and well-being of the people who use our products is our number one priority. Rare cases of the neurological disorder, Guillain-Barré syndrome have been reported following vaccination with the Janssen COVID-19 vaccine. Most occurred within 42 days after vaccination. While the chance of having this occur is very low, Johnson & Johnson has updated its COVID-19 Vaccine Factsheet to include important information about these rare cases and on the signs and symptoms of Guillain-Barré syndrome. Updates with this new information will be implemented in other regions of the wo...
Source: Johnson and Johnson - July 12, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Case Reports Identify Guillain-Barr é Variants After COVID Vaccine Case Reports Identify Guillain-Barr é Variants After COVID Vaccine
Report findings from India and the UK ' should prompt all physicians to be vigilant in recognizing Guillain-Barr é syndrome in patients who have received the AstraZeneca vaccine, ' investigators say.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - July 1, 2021 Category: Infectious Diseases Tags: Neurology & Neurosurgery News Source Type: news
Seven Cases of Guillain-Barr é Noted After COVID-19 Vaccine in India
MONDAY, June 28, 2021 -- Cases of Guillain-Barr é syndrome (GBS) have been reported after receipt of the Oxford-AstraZeneca severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, according to two reports published online June 10 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 28, 2021 Category: Pharmaceuticals Source Type: news
Four men develop life-threatening condition after receiving AstraZeneca jab - symptoms
THE ASTRAZENECA vaccine is set to come under intense scrutiny once again after four British men developed a potentially life-threatening condition shortly after receiving the jab. The vaccine recipients developed Guillain-Barr é syndrome - a potentially deadly condition. What are the symptoms? (Source: Daily Express - Health)
Source: Daily Express - Health - June 22, 2021 Category: Consumer Health News Source Type: news
Four Brits develop Guillain-Barré syndrome just days after having AstraZeneca's Covid jab
Four cases of potentially deadly Guillain-Barré syndrome - in which the body's immune system breaks down - were recorded in Nottingham just 11 to 12 days after having the vaccine. (Source: the Mail online | Health)
Source: the Mail online | Health - June 22, 2021 Category: Consumer Health News Source Type: news
AstraZeneca Covid vaccine linked to rare neurological disorder in India, UK
In Guillain-Barre syndrome (GBS), the body's immune system mistakenly attacks part of its peripheral nervous system --the network of nerves located outside of the brain and spinal cord. (Source: The Economic Times)
Source: The Economic Times - June 22, 2021 Category: Consumer Health News Source Type: news
Rare neurological disorder documented following COVID-19 vaccination
(Wiley) In two separate articles in the Annals of Neurology, clinicians in India and England report cases of a rare neurological disorder called Guillain-Barre? syndrome after individuals were vaccinated against COVID-19. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 21, 2021 Category: International Medicine & Public Health Source Type: news
Covid symptoms: Signs in the feet to spot - from skin lesions to Guillain-Barre Syndrome
COVID symptoms are being widely investigated - how the virus affects all areas of the body. A new review paper has looked at the clinical manifestations of COVID-19 in the feet, finding vascular, dermatological and neurological symptoms have been reported. (Source: Daily Express - Health)
Source: Daily Express - Health - June 7, 2021 Category: Consumer Health News Source Type: news
AIDP or Guillain-barre Syndrome Associated With COVID-19 AIDP or Guillain-barre Syndrome Associated With COVID-19
Was this patient ' s Guillain-Barre Syndrome a sequela of COVID-19? This case highlights the need for physicians to be aware of this possible complication when evaluating COVID-19 patients.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 3, 2021 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news
Guillain-Barre Syndrome
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - May 20, 2021 Category: General Medicine Source Type: news
AstraZeneca vaccine reactions: Blood clots still 'very rare' – other side effects to note
THE ASTRAZENECA Covid vaccine is now under investigation from the European Medicines Agency . This follows recipients of the jab developing Guillain-Barre syndrome - another side effect connected to the vaccine. (Source: Daily Express - Health)
Source: Daily Express - Health - May 7, 2021 Category: Consumer Health News Source Type: news
COVID-19 Vaccine and Guillain-barre Syndrome COVID-19 Vaccine and Guillain-barre Syndrome
In this commentary, the authors warn against jumping to conclusions regarding an association of COVID-19 vaccines with Guillain-Barre syndrome, even if sporadic cases of GBS emerge.Brain (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - April 12, 2021 Category: Intensive Care Tags: Neurology & Neurosurgery Journal Article Source Type: news
No Proof COVID Vaccines Can Trigger Guillain-Barr é Syndrome
WEDNESDAY, April 7, 2021 -- Two people in the Johnson& Johnson COVID-19 vaccine trial developed Guillain-Barré syndrome, but it ' s highly doubtful the vaccine is to blame, according to a just-published case study.
Although both people... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 7, 2021 Category: General Medicine Source Type: news
No Association Between COVID-19 and Guillain-Barré Syndrome
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - March 28, 2021 Category: Orthopaedics Tags: Snapshot Source Type: news
Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV
TITUSVILLE, N.J., January 21, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen’s 25-year commitment to make HIV history. In the U.S., ViiV Healthcare is the marketing authorization holder for CABENUVA.C...
Source: Johnson and Johnson - January 22, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
